SEC Filings

S-1
AVEXIS, INC. filed this Form S-1 on 01/15/2016
Entire Document
 

Table of Contents

Dr. Genecov resulting from the acceleration of certain stock options held by Mr. Carbona in connection with the termination of his employment.

Name(1)
 
Option
Awards ($)
 
All Other
Compensation ($)
 
Total ($)
 

John A. Carbona(2)

             

John D. Harkey, Jr.(3)

    167,684 (5)       167,684  

David G. Genecov M.D.(4)

    167,684 (5)       167,684  

Brian K. Kaspar, Ph.D.(6)

        90,000 (7)   90,000  

Bong Y. Koh(8)

             

Paul B. Manning

             

Jonathan Leff

             

Carole Nuechterlein

             

Frank Verwiel(9)

             

(1)
On June 8, 2015, Mr. Nolan joined the board in connection with his service as our Chief Executive Officer. Mr. Nolan did not receive any compensation in 2015 for services provided as a member of our board of directors.

(2)
Mr. Carbona was an employee director from January 1, 2015 through April 22, 2015 and his compensation during this period in 2015 is fully reflected in "Executive Compensation — Summary Compensation Table" below. From April 23, 2015 through June 15, 2015, Mr. Carbona served as a non-employee director of the Company. Mr. Carbona did not receive any compensation in 2015 for services provided as a member of our board of directors. Mr. Carbona ceased serving on the board on June 15, 2015.

(3)
Mr. Harkey ceased serving on the board on October 8, 2015.

(4)
Dr. Genecov ceased serving on the board on June 10, 2015.

(5)
We did not grant any stock options to our non-employee directors in 2015 for their service on our board of directors. The amounts reported in this column for Mr. Harkey and Dr. Genecov represent, for each director, one-third of the incremental fair value of the modification of the portion of Mr. Carbona's stock option awards, as computed in accordance with ASC 718 as of the modification date on April 22, 2015, that were accelerated in connection with the termination of Mr. Carbona's employment, to which each of Mr. Harkey and Dr. Genecov had the right to purchase under the terms of the Stock Purchase and Option Agreement described in "Executive Compensation—Equity-Based Awards—Stock Purchase and Option Agreement" below. See "Executive Compensation—Payments upon Termination or Change in Control" below for a discussion of the acceleration of the 39,000 unvested stock options held by Mr. Carbona at the time of the termination of his employment. We determined that the acceleration of vesting was a Type III modification pursuant to ASC 718. Therefore, we recognized the amount immediately since the awards did not require further service.

(6)
As of December 31, 2015, the number of unvested stock awards held by Dr. Kaspar was 1,268,691. Dr. Kaspar did not have any outstanding option awards as of December 31, 2015.

(7)
This amount represents cash consulting fees paid to Dr. Kaspar pursuant to his consulting agreement.

(8)
Mr. Koh joined the board in June 2015.

(9)
Mr. Verwiel joined the board in December 2015.

147



© AveXis, Inc. All Rights Reserved.